Clinically "silent" weight loss associated with mycophenolate mofetil in pediatric renal transplant recipients

Pediatric Transplantation

Volumn 12, Issue 1, 2008, Pages 113-116

  Laskin, Benjamin ^a   Goebel, Jens ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Kidney transplantation; Mycophenolate mofetil; Pediatrics; Weight loss

Indexed keywords

AMLODIPINE; AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; QUETIAPINE; VALPROATE SEMISODIUM;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; KIDNEY DYSPLASIA; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; SIDE EFFECT; WEIGHT REDUCTION;

ADOLESCENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MYCOPHENOLIC ACID; POSTOPERATIVE PERIOD; URETHRAL OBSTRUCTION; WEIGHT LOSS;

EID: 37849018395     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00840.x     Document Type: Article

References (15)

1. Ettenger R, Sarwal MM. Mycophenolate mofetil in pediatric renal transplantation. Transplantation 2005 : 80 (Suppl. 2 S201 S210.
2. Hocker B, Weber LT, Bunchman T, Rashford M, Tonshoff B, Tricontinental MMF Suspension Study Group. Mycophenolate mofetil suspension in pediatric renal transplantation: Three-year data from the tricontinental trial. Pediatr Transplant 2005 : 9 : 504 511.
3. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management. Drug Saf 2001 : 24 : 645 663.
4. Neu AM, Benfield M. What is the role for mycophenolate mofetil in pediatric renal transplantation? Pediatr Transplant 1999 : 3 : 83 87.
5. Butani L, Palmer J, Baluarte HJ, Polinsky MS. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation 1999 : 68 : 83 86.
6. Roberti I, Reisman L. A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients. Pediatr Transplant 1999 : 3 : 231 235.
7. Virji M, Carter JE, Lirenman DS. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients. Pediatr Transplant 2001 : 5 : 293 296.
8. Jacqz-Aigrain E, Khan Shaghaghi E, Baudouin V, et al. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol 2000 : 14 : 95 99.
9. Berribi C, Loirat C, Jacqz-Aigrain E. Mycophenolate mofetil may induce apoptosis in duodenal villi. Pediatr Nephrol 2000 : 14 : 177 178.
10. Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil induced villous atrophy. Transplantation 1998 : 66 : 1115 1116.
11. Kamar N, Faure P, Dupuis E, et al. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int 2004 : 17 : 463 467.
12. De Paula Meneses R, Kotsifas CH, Olandoski KP. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in children with stable renal transplant. Am J Transplant 2006 : 6 : 510 (abstract no. 1315).
13. Kamar N, Oufroukhi L, Faure P, et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 2005 : 20 : 2231 2236.
14. Goebel J, Logan B, Maseck D, Derotte M, Tarabishi R, vinks S. Pharmacokinetic, -dynamic and clinical variability of mycophenolate mofetil in pediatric kidney transplantation. Pediatr Transplant 2007 : 11 : 59. (abstract no. 106).
15. Knoll GA, Macdonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003 : 14 : 2381 2386.